1
EXHIBIT 11
NOVAMETRIX MEDICAL SYSTEMS INC.
STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS
QUARTER ENDED YEAR ENDED
-------------------- -----------------------------------
07-30-95 07-31-94 04-30-95 05-01-94 05-02-93
-------- -------- -------- -------- --------
PRIMARY EARNINGS PER SHARE:
Weighted average number of shares
of Common Stock outstanding 5,851,621 5,104,322 5,591,536 4,504,865 4,184,671
Net effect of dilutive common stock
equivalents (1) 2,244,456 2,245,103 2,058,410 2,091,246 2,055,353
Total weighted average number of
shares of Common Stock and
dilutive common stock equivalents ---------- ---------- ---------- ---------- ----------
outstanding 8,096,077 7,349,425 7,649,946 6,596,111 6,240,024
========== ========== ========== ========== ==========
FULLY DILUTED EARNINGS PER SHARE:
Weighted average number of shares
of Common Stock outstanding 5,851,621 5,104,322 5,591,536 4,504,865 4,184,671
Net effect of dilutive common stock
equivalents (1) 2,244,456 2,264,391 2,177,307 2,124,565 2,064,193
Total weighted average number of
shares of Common Stock and
dilutive common stock equivalents ---------- ---------- ---------- ---------- ----------
outstanding 8,096,077 7,368,713 7,768,843 6,629,430 6,248,864
========== ========== ========== ========== ==========
NET INCOME $ 388,167 $ 204,174 $1,604,367 $ 754,720 $ 264,917
Per common share amounts:
Primary $ .05 $ .03 $ .21 $ .11 $ .04
Fully Diluted $ .05 $ .03 $ .21 $ .11 $ .04
- ---------------
(1) Earnings per common share amounts were computed by dividing net income by
the weighted average number of shares of Common Stock and dilutive common
stock equivalents outstanding during the period. Common stock equivalents
consist of the Company's Preferred Stock, stock options, warrants and
shares subscribed under the Company's employee stock purchase plan. The
computation of dilutive common stock equivalents are based on the
if-converted method for the Preferred Stock and on the treasury stock
method for the other common stock equivalents using the average market
price for the primary earnings per share computations and the higher of
average or period-end market price for the fully diluted earnings per
share computations.